Familial Hypercholesterolemia Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Verve Therapeutics, LIB Therapeutics, Arrowhead Pharma, Regeneron Pharma

The Key Familial Hypercholesterolemia Companies in the market include - Verve Therapeutics, LIB Therapeutics, Arrowhead Pharmaceuticals, Regeneron Pharmaceuticals, Amgen, and others.

DelveInsight's "Familial Hypercholesterolemia Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Familial Hypercholesterolemia, historical and forecasted epidemiology as well as the Familial Hypercholesterolemia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Familial Hypercholesterolemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Familial Hypercholesterolemia Market Forecast [https://www.delveinsight.com/sample-request/familial-hypercholesterolemia-market-report?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Familial Hypercholesterolemia Market Report:

*
The Familial Hypercholesterolemia market size is anticipated to grow with a significant CAGR of 12% during the study period (2020-2034)

*
In July 2024, NewAmsterdam Pharma achieved a significant milestone in its Phase III clinical program, with its lead cardiovascular candidate, obicetrapib, demonstrating cholesterol-lowering efficacy in the pivotal BROOKLYN trial (NCT05425745). This trial, the first of four in the company's portfolio, evaluates obicetrapib in adult patients with heterozygous familial hypercholesterolemia (HeFH) who have inadequately controlled LDL-C levels despite receiving the highest tolerable doses of lipid-lowering therapies.

*
DelveInsight's epidemiology model estimates that in 2023, there were approximately 361 thousand diagnosed cases of Familial Hypercholesterolemia in the US. This number is expected to grow during the forecast period (2024-2034), driven by heightened awareness, expanded screening, and advancements in genetic testing.

*
In 2023, France reported the highest number of diagnosed prevalent cases of Familial Hypercholesterolemia among the EU4 and the UK, with around 58 thousand cases, followed by the UK with approximately 54 thousand cases, and Germany with nearly 53 thousand cases.

*
In the US, the highest number of diagnosed prevalent cases of Familial Hypercholesterolemia in 2023 were seen in the 50-59 years age group, with approximately 94 thousand cases, while the lowest number was observed in the 30-39 years age group, with around 27 thousand cases.

*
In 2023, Japan had the second-highest number of diagnosed prevalent cases of Familial Hypercholesterolemia among the 7MM, with approximately 69 thousand cases.

*
Key Familial Hypercholesterolemia Companies: Verve Therapeutics, LIB Therapeutics, Arrowhead Pharmaceuticals, Regeneron Pharmaceuticals, Amgen, and others

*
Key Familial Hypercholesterolemia Therapies: VERVE-101, Lerodalcibep, Zodasiran, EVKEEZA (evinacumab-dgnb), PRALUENT (alirocumab), REPATHA (evolocumab), and others

*
The Familial Hypercholesterolemia epidemiology based on mutation-specific cases analyzed that a mutation in the LDLR gene accounted for the highest diagnosed prevalent cases in the US

*
The Familial Hypercholesterolemia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Familial Hypercholesterolemia pipeline products will significantly revolutionize the Familial Hypercholesterolemia market dynamics.

Familial Hypercholesterolemia Overview

Familial Hypercholesterolemia is a genetic disorder characterized by high levels of low-density lipoprotein (LDL) cholesterol in the blood. It is caused by mutations in the genes responsible for regulating cholesterol levels, such as the LDL receptor gene. Individuals with FH have a higher risk of developing cardiovascular diseases, including heart attacks, at a younger age due to the accumulation of cholesterol in their arteries. FH can be inherited in an autosomal dominant pattern, meaning one copy of the mutated gene from either parent is sufficient to cause the disorder. Early diagnosis and treatment, often with cholesterol-lowering medications, are essential to manage the condition and reduce the risk of complications.

Get a Free sample for the Familial Hypercholesterolemia Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/familial-hypercholesterolemia-market-report [https://www.delveinsight.com/report-store/familial-hypercholesterolemia-market-report?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Familial Hypercholesterolemia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Familial Hypercholesterolemia Epidemiology Segmentation:

The Familial Hypercholesterolemia market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Diagnosed Prevalent Cases of Familial Hypercholesterolemia in the 7MM

*
Mutation-specific Diagnosed Prevalent Cases of Familial Hypercholesterolemia in the 7MM

Download the report to understand which factors are driving Familial Hypercholesterolemia epidemiology trends @ Familial Hypercholesterolemia Epidemiology Forecast [https://www.delveinsight.com/sample-request/familial-hypercholesterolemia-market-report?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Familial Hypercholesterolemia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Familial Hypercholesterolemia market or expected to get launched during the study period. The analysis covers Familial Hypercholesterolemia market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Familial Hypercholesterolemia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Familial Hypercholesterolemia Therapies and Key Companies

*
VERVE-101: Verve Therapeutics

*
Lerodalcibep: LIB Therapeutics

*
Zodasiran: Arrowhead Pharmaceuticals

*
EVKEEZA (evinacumab-dgnb): Regeneron Pharmaceuticals

*
PRALUENT (alirocumab): Sanofi/ Regeneron Pharmaceuticals

*
REPATHA (evolocumab): Amgen

Discover more about therapies set to grab major Familial Hypercholesterolemia market share @ Familial Hypercholesterolemia Treatment Landscape [https://www.delveinsight.com/sample-request/familial-hypercholesterolemia-market-report?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Familial Hypercholesterolemia Market Strengths

*
The clarity in disease understanding and pathogenesis has driven the development of novel pharmacological options like PCSK9 inhibitors, ANGPTL3 inhibitors, and MTP inhibitor

*
Updated international diagnostic and clinical guidelines for FH and HoFH enable evidence-based therapeutic approaches and screening strategies for early identification

*
Advances in research have led to the discovery of novel molecules like siRNA and recombinant fusion protein that may offer novel options to lower LDL significantly

Familial Hypercholesterolemia Market Opportunities

*
Preclinical studies have yielded gene therapy and CRISPR-based gene editing approaches; conducting further research and clinical trials may offer curative therapy.

*
Current therapies do not impart sufficient cholesterol-lowering allowing pharma players to bring newer, more potent, and better LDL-C lowering therapies and prevent ASCVD in HoFH patients.

*
Advancements in healthcare technologies and digital health solutions can potentially enhance early detection and personalized management of HoFH.

Scope of the Familial Hypercholesterolemia Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Familial Hypercholesterolemia Companies: Verve Therapeutics, LIB Therapeutics, Arrowhead Pharmaceuticals, Regeneron Pharmaceuticals, Amgen, and others

*
Key Familial Hypercholesterolemia Therapies: VERVE-101, Lerodalcibep, Zodasiran, EVKEEZA (evinacumab-dgnb), PRALUENT (alirocumab), REPATHA (evolocumab), and others

*
Familial Hypercholesterolemia Therapeutic Assessment: Familial Hypercholesterolemia current marketed and Familial Hypercholesterolemia emerging therapies

*
Familial Hypercholesterolemia Market Dynamics: Familial Hypercholesterolemia market drivers and Familial Hypercholesterolemia market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Familial Hypercholesterolemia Unmet Needs, KOL's views, Analyst's views, Familial Hypercholesterolemia Market Access and Reimbursement

To know more about Familial Hypercholesterolemia companies working in the treatment market, visit @ Familial Hypercholesterolemia Clinical Trials and Treatments [https://www.delveinsight.com/sample-request/familial-hypercholesterolemia-market-report?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Familial Hypercholesterolemia Market Report Introduction

2. Executive Summary for Familial Hypercholesterolemia

3. SWOT analysis of Familial Hypercholesterolemia

4. Familial Hypercholesterolemia Patient Share (%) Overview at a Glance

5. Familial Hypercholesterolemia Market Overview at a Glance

6. Familial Hypercholesterolemia Disease Background and Overview

7. Familial Hypercholesterolemia Epidemiology and Patient Population

8. Country-Specific Patient Population of Familial Hypercholesterolemia

9. Familial Hypercholesterolemia Current Treatment and Medical Practices

10. Familial Hypercholesterolemia Unmet Needs

11. Familial Hypercholesterolemia Emerging Therapies

12. Familial Hypercholesterolemia Market Outlook

13. Country-Wise Familial Hypercholesterolemia Market Analysis (2020-2034)

14. Familial Hypercholesterolemia Market Access and Reimbursement of Therapies

15. Familial Hypercholesterolemia Market Drivers

16. Familial Hypercholesterolemia Market Barriers

17. Familial Hypercholesterolemia Appendix

18. Familial Hypercholesterolemia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=familial-hypercholesterolemia-market-forecasted-to-surge-in-coming-years-20242034-analysis-by-delveinsight-verve-therapeutics-lib-therapeutics-arrowhead-pharma-regeneron-pharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.